You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 254 No. 18, November 8, 1985 TABLE OF CONTENTS
  JAMA
  •  Online Features
  COUNCIL REPORT
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Saccharin

Review of Safety Issues

Council on Scientific Affairs

JAMA. 1985;254(18):2622-2624.


Abstract

This report reviews the experimental and epidemiologic data related to the carcinogenicity of saccharin. The results of animal studies suggest a species and organ effect. In single-generation studies in rats, mice, hamsters, and monkeys, saccharin did not induce cancer in any organ. In two-generation studies involving rats, however, there was evidence that the incidence of bladder tumors was significantly greater in saccharin-treated males of the second generation than in controls; the development of bladder tumors in rats seems to be a species- and organ-specific phenomenon for which there is currently no explanation. In humans, available evidence indicates that the use of artificial sweeteners, including saccharin, is not associated with an increased risk of bladder cancer. Until there is firm evidence of its carcinogenicity in humans, saccharin should continue to be available as a food additive, and reports of adverse health effects associated with its use should be monitored.

(JAMA 1985;254:2622-2624)



Author Affiliations

From the Council on Scientific Affairs, Division of Drugs and Technology, American Medical Association, Chicago.


Footnotes

This report was adopted as amended by the House of Delegates of the American Medical Association at the Annual Meeting, June 1985.

This report is not intended to be construed or to serve as a standard of medical care. Standards of medical care are determined on the basis of all the facts and circumstances involved in an individual case and are subject to change as scientific knowledge and technology advance and patterns of practice evolve. This report reflects the views of scientific literature as of 1984.

Reprint requests to Council on Scientific Affairs, Division of Drugs and Technology, American Medical Association, 535 N Dearborn St, Chicago, IL 60610 (John C. Ballin, PhD).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

"Inactive" Ingredients in Pharmaceutical Products: Update (Subject Review)
Committee on Drugs
Pediatrics 1997;99:268-278.
ABSTRACT | FULL TEXT  

Drug Therapy in Pregnancy and Lactation
Frey and O'Donnell
Journal of Pharmacy Practice 1989;2:2-12.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.